Sign in

You're signed outSign in or to get full access.

Travis Whitfill

Chief Operating Officer at Azitra
Executive
Board

About Travis Whitfill

Travis Whitfill is Azitra’s co-founder, Chief Operating Officer (since June 2023), and a director serving on the Board since inception. He previously served as Chief Scientific Officer (Jan 2014–Sep 2019) and Director of Advanced Technology (since Sep 2019). He earned a B.S. from Dallas Baptist University, an MPH from Yale University, and a PhD from University College London, has led multiple grant-funded projects, holds several patents, and co-authored 70+ publications. Age 35 as of the 2025 proxy; no company TSR, revenue or EBITDA growth metrics are disclosed for his tenure in the proxy materials .

Past Roles

OrganizationRoleYearsStrategic Impact
Azitra, Inc.Chief Scientific Officer2014–2019Built scientific foundation; advanced live biotherapeutic programs
Azitra, Inc.Director of Advanced Technology2019–presentLed technology strategy and innovation
Azitra, Inc.Chief Operating OfficerJun 2023–presentOperational leadership through clinical and financing milestones

External Roles

OrganizationRoleYearsStrategic Impact
Bios Equity Partners, LPPartner2015–2023VC investing; biotech portfolio support
Bios ResearchSenior Analyst2014–2023Equity research in life sciences
Yale UniversityAssociate Research Scientist; Assistant Professor Adjunct2016–2022; 2022–presentAcademic research in Pediatrics and Emergency Medicine
IN8Bio, Inc. (Nasdaq: INAB)Director2018–May 2025Public company governance in oncology
410 MedicalDirector2017–2019Medtech oversight
SIRPant ImmunotherapeuticsDirector2021–2023Immunotherapy venture governance

Fixed Compensation

Metric20232024
Base Salary ($)$158,846 $380,000
Target Bonus (%)Up to 30% of base salary Up to 30% of base salary
Actual Bonus Paid ($)$0 $88,350
Option Awards ($, grant-date fair value)$20,700 $0
All Other Compensation ($)$2,767 $4,460
Total ($)$182,313 $472,810
Employment Agreement TermsDetail
Agreement dateJuly 5, 2023
RoleChief Operating Officer
Base Salary$350,000
Target BonusUp to 30% of base salary; based on Board-set performance parameters
BenefitsHealth insurance and other executive benefits at company expense
Employment StatusAt-will; either party may terminate with notice

Performance Compensation

Metric CategoryWeightingTargetActualPayout ($)Vesting/Timing
Company-wide metrics: pre-clinical, clinical & regulatory, financial, investor relationsNot disclosedUp to 30% of base salary Company achieved 75% of metrics; individual payouts adjusted by goal attainment and job-level weighted score 88,350 (FY2024) Cash bonus for FY2024; paid per Compensation Committee approval

Notes: The proxy discloses qualitative performance categories and that FY2024 bonuses were calibrated to 75% achievement with role-based weighting; specific metric weights and targets are not disclosed .

Option Awards — Grant Detail and Vesting

Grant DateInstrumentSharesStrike ($)VestingExpiration
Sep 8, 2023Stock Options33362.1025% cliff at 1st anniversary (83 sh); remaining 75% monthly over 36 months post-anniversary (250 sh)Sep 8, 2033

Equity Ownership & Alignment

Ownership MetricValue
Total beneficial ownership (common shares)14,394 shares (<1% of 17,226,354 outstanding as of May 28, 2025)
Options — exercisable1,859 @ $14.32 expiring Jan 1, 2026; 1,246 @ $51.08 expiring Dec 16, 2030; 111 @ $62.10 expiring Sep 8, 2033
Options — unexercisable222 @ $62.10 expiring Sep 8, 2033 (continues to vest ratably monthly)
RSUs/PSUsNone disclosed for Whitfill
Hedging/PledgingCompany Insider Trading Policy prohibits short sales, publicly traded options, hedging transactions, margin accounts, and pledged securities for directors/officers/employees
Stock Ownership GuidelinesNot disclosed in proxy materials
Trading WindowsInsider Trading Policy applies; preclearance and window practices implied via policy and SEC compliance

Employment Terms

TermWhitfill (COO)
Severance on qualified involuntary termination (without cause/incapacity)Continuation of base salary for 6 months; plus prior-year annual bonus if unpaid
Illustrative cash severance (had termination occurred 12/31/2024)$278,350 (includes $190,000 salary and $88,350 bonus)
Change-in-control treatmentCash severance available before/after change in control; no equity acceleration shown for Whitfill at 12/31/2024
IP/Confidentiality/IndemnificationCustomary provisions in agreement
Non-compete/Non-solicit/Garden leaveNot disclosed in proxy materials

Board Governance (Director Service)

  • Board service: Director since inception; not independent due to executive officer status .
  • Board composition: Four directors; two independent (Barbara Ryan, John Schroer) per NYSE American rules for smaller reporting companies (50% independence threshold met) .
  • Committees and roles: Audit Committee (Ryan, Schroer; Schroer chair); Compensation Committee (Ryan chair, Schroer); Nominating & Corporate Governance Committee (Ryan chair, Schroer). Committees consist solely of independent directors; Whitfill does not serve on committees .
  • Attendance: In 2024, Board held four meetings; all directors attended at least 75% of Board and committee meetings. Schroer and Ryan attended the 2024 annual meeting; others did not; no policy requiring annual meeting attendance .
  • Board leadership: No formal policy to separate chairperson and CEO; no lead independent director. Risk oversight delegated across committees, reporting to full Board .
  • Director compensation policy: Executive directors are not compensated for Board service. Non-executive directors receive cash retainers (Board: $25,000; Committee chairs: $5,000 for Compensation and Nominating, $7,500 for Audit; Committee members: $3,500) and previously received 333-option grants in Sep 2023 with $62.10 strike and standard vesting .

Related Party Transactions, Clawbacks, Policies

  • Related party transactions: None exceeding SEC thresholds since Jan 1, 2023, other than compensation arrangements described in the proxy .
  • Clawback/Recoupment policy: Not disclosed in proxies reviewed; Insider Trading Policy attached to 2024 10-K, with prohibitions on hedging/pledging and specified speculative transactions .
  • Indemnification: Company provides indemnification to officers/directors per charter/bylaws and written agreements; standard DGCL limitations of liability apply .

Risk Indicators & Red Flags

  • Dilution risk: Equity line with Alumni Capital LP up to $20 million through Dec 31, 2026; already sold 2,247,000 shares by May 28, 2025. Could increase volatility and impact insider alignment via dilution of ownership stakes .
  • Option overhang and expirations: Multiple options are in-the-money/out-of-the-money with staggered expirations, including a near-term 2026 expiry at $14.32, potentially influencing exercise/sale decisions when trading windows open .
  • Governance dual-role: Executive-director status reduces board independence; however, committees are fully independent and chaired by non-executives, which mitigates some concerns .
  • Clawback transparency: Lack of disclosed clawback policy reduces pay-for-performance enforcement clarity relative to evolving listing standards .

Investment Implications

  • Pay-for-performance linkage: Whitfill’s bonus structure is explicitly tied to company-wide operational/financial/IR metrics with role-based weighting; FY2024 payout of $88,350 against a 30% target indicates moderate alignment, contingent on milestone execution .
  • Retention risk: Severance equals six months of salary plus prior-year bonus (if unpaid) and no equity acceleration shown for Whitfill; retention rests on ongoing equity vesting schedules and operational milestones rather than rich change-in-control benefits, lowering “golden parachute” risk .
  • Trading signals: Prohibition on hedging/pledging reduces adverse alignment behaviors; absence of Form 4 activity located suggests limited recent insider selling signals for Whitfill, while the monthly vesting of 2023 options and 2026/2030/2033 expirations create predictable windows for potential exercises/sales that traders should monitor around earnings and news cycles .
  • Governance quality: Dual executive-director role is counterbalanced by independent committee structures and active oversight, but the absence of a lead independent director and no disclosed clawback policy are governance watch points for investors .

Appendix: Outstanding Equity Awards (as of Dec 31, 2024)

NameExercisable Options (#)Unexercisable Options (#)Strike ($)Expiration
Travis Whitfill1,859014.3201/01/2026
Travis Whitfill1,246051.0812/16/2030
Travis Whitfill11122262.1009/08/2033

Appendix: Beneficial Ownership (as of May 28, 2025)

HolderShares Beneficially Owned% of Outstanding
Travis Whitfill14,394<1% (of 17,226,354 shares outstanding)

Sources

  • DEF 14A (May 29, 2025): Biography, compensation tables, employment agreements, committees, beneficial ownership, policies .
  • DEF 14A (Oct 9, 2024): Prior compensation details, equity awards, termination payments, employment agreements .